X

Trial Profile

An exploratory study of SHR-1701 in combination with Famitinib in patients with Advanced Pancreatic cancer and Biliary Tract Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Famitinib (Primary) ; Retlirafusp alfa (Primary)
Indications Biliary cancer; Pancreatic cancer
Focus Therapeutic Use

Most Recent Events

25 Oct 2024 Results (n=45;as of May 1, 2024) evaluating the efficacy and safety of SHR-1701 combined with famitinib in patients with advanced BTC or PDAC who failed previous standard treatment presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics.
22 Jan 2022 Results (as of 15 Sep 2021; n= 24) presented at the 2022 Gastrointestinal Cancers Symposium.
16 Nov 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com